UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Which multinational drugmaker grew most rapidly in H1?
  • By Nam Doo-hyun
  • Published 2018.07.25 11:52
  • Updated 2018.07.25 11:52
  • comments 0

Daiichi Sankyo Korea achieved the most substantive sales growth among multinational pharmaceutical companies operating in Korea in the first half,

According to U-BIST data of 19 multinationals with outpatient prescription sales exceeding 20 billion won ($17.7 million) in the first half, the Korean unit of Daiichi Sankyo’s sales surged 22.6 percent year-on-year, which was the highest among the 19 firms.

Daiichi Sankyo Korea’s outpatient prescriptions rose to 55.7 billion won in the first half from 45.5 billion won a year earlier.

A spike in prescriptions of Lixiana (ingredient: edoxaban), a non-vitamin K antagonist oral anticoagulant, helped to boost the sales of Daiichi Sankyo in the first half, observers said.

Santen Pharmaceutical Korea ranked second in sales growth, marking a 17 percent increase in revenue to hit 27.3 billion won in the first half. The company’s first-half sales last year recorded 23.4 billion won.

Santen Pharmaceutical Korea enjoyed advantages from selling artificial tear drops Diquas-S when the fine dust problem gripped the nation last year. Diquas-S is a follow-up product to Diquas.

Prescriptions of Lilly Korea drugs reached 24.6 billion won in the first half, up 15.7 percent year-on-year.

The revenue growth was attributed to an increase in prescriptions of Trulicity, an antidiabetic drug.

Since the market release in 2015, Trulicity’s sales have been surging. Its annual revenue exceeded 12 billion won within a year and a half after the launch.

On the other hand, Gilead Sciences Korea’s outpatient prescriptions plummeted 21.8 percent in the first half from a year earlier, due to sales declines of hepatitis C treatments Sovaldi and Harvoni that lost competition against late-runners. With hepatitis C cure rates going up, the number of patients plunged, which also contributed to the drop in sales of Sovaldi and Harvoni.

Pfizer Korea topped outpatient prescriptions in the first half, followed by MSD Korea, AstraZeneca Korea, Novartis Korea, Boehringer Ingelheim, Gilead Sciences Korea, Astellas Korea, GSK, Bayer Korea, and Takeda Pharmaceuticals Korea.

hwz@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Nam Doo-hyun
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top